The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...

WAKE-UP CALL: 104m Indians or 11% of the population suffer from obstructive sleep apnea, according to a 2023 AIIMS study ...

From sleep apnea notifications to a number of new health and fitness tools, WatchOS 11 adds a lot of new functionality to ...

The FDA also recommends that prescribed users reduce their caloric intake and increase their exercise The weight loss drug ...

“People who experience SRED are at an increased risk of fatigue, depression and weight gain,” Johnston said. They’re also at ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

According to the American College of Sports Medicine, the No. 1 trend for 2025 is wearable technology.

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

FDA approves Zepbound for obstructive sleep apnea in obese individuals Discover how this weight-loss drug reduces symptoms ...

On December 20, 2024, pharmaceutical company Eli Lilly announced that the FDA approved its first and only obstructive sleep ...